The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
about
Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cellsThe relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell linesPhase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.Demethylating Agents in the Treatment of CancerDownregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemiaDecitabine in the treatment of myelodysplastic syndromes.Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaSLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro studyPhysiological and pharmacological roles of nucleoside transporter proteins.In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells.Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cellsNucleic Acid Bioconjugates in Cancer Detection and Therapy.Contribution of tumoral and host solute carriers to clinical drug response.High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549 tumor cells grown as tumor xenografts in vivo.Digging deep into "dirty" drugs - modulation of the methylation machinery.Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.Molecular mechanisms of drug resistance in acute myeloid leukaemia.Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitorsIdentifying genetic variants that contribute to chemotherapy-induced cytotoxicityPopulation-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.Genetic factors influencing cytarabine therapy.Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.Human nucleoside transporters: biomarkers for response to nucleoside drugs.Drug transporter pharmacogenetics in nucleoside-based therapies.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.Pediatric acute myeloid leukemia.Nucleoside transporters: biological insights and therapeutic applications.Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.The mechanistic role of DNA methylation in myeloid leukemogenesis.Clinical potential of elacytarabine in patients with acute myeloid leukemia.SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell linesNucleoside analogs: ready to enter the era of precision medicine?Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.
P2860
Q24654966-2A6A55C6-5363-4F1B-82CE-00B529F9AE1FQ33245149-C2558D52-BD07-4CFF-91DB-0918166BE06DQ33389485-70F7B270-024B-4224-B14D-7B63916D374CQ33678040-E1CE532C-6CC3-4EA1-BD0A-ED5683710A25Q33890300-C4C80125-D78E-40A3-B482-61280972593BQ33922485-92F65D50-CF71-4D8D-8955-1019B45A7BBEQ34088403-5BDB698A-937C-4EAD-AC20-D2D22B78EC02Q34314177-450966C5-6F9C-43B2-8B70-9E897A481CEBQ34528361-1843C2F2-5858-4973-9886-C93043142480Q34792283-C1C69A66-B26B-493F-87A7-A4126DA91099Q35286787-F92D36EC-F69D-46DF-9CE3-08E74822FDE8Q35668858-B820A551-DF49-4D20-BFD6-0B4BE12920DBQ35832499-39885B82-DA1E-4DCE-936F-6D960F559C46Q35867875-7392E2E0-C2FD-4309-8D89-BC9480FF785EQ35946876-0E64798C-044D-49E1-971E-3C3E200F75A1Q36075226-CA7315F2-49FA-4945-A7D5-48DFE6B5ED3FQ36338979-0918F881-AAF0-4CCC-BF94-85A37440B3CCQ36523796-72177F78-0E92-432A-982C-8847618DC3BEQ36609590-13CB8251-EAE4-45F4-A887-9B824CF9F663Q36835812-15962063-81A9-4AC0-87EB-FD0C96A69DAAQ36900856-510028D4-2266-4CA1-8A4F-AE83A47728C2Q36966019-A736C8F5-C79D-4499-9AF4-4C19174C3DE8Q37119899-F93FFFA9-D29F-4A16-9521-A32FE60F2707Q37295110-348D0409-05AA-4B19-9AA3-5E1A4538D58BQ37580317-0AC8186B-B41E-4F94-8B1B-22CCBB8C0A26Q37618228-F24A4DCA-228B-477B-9628-8A41C740D201Q37627821-5C568019-7B35-4733-90D7-463D06910526Q37698437-40E90646-DF93-4374-ADB2-58731A502DBAQ37760954-1268C793-27E4-483B-BF0C-9B3D34D1608DQ37963498-94A253F9-39B1-4EE4-BCAB-47B395135329Q37988570-2AC78C33-9FC9-4E08-B5DC-1F574E42D4B5Q38031634-91B0374F-8121-48CF-A3DB-FE50DFCB64AAQ38078423-517611A9-FF9A-46D6-B8DA-8574CEEC0F0FQ38218971-7C678051-7983-4746-B4B2-35F5A4BF2657Q38282095-FBE491D4-D2E3-43DF-88D7-55361C033254Q38757910-976FA032-5226-480C-99EA-3797FBA8903BQ38762107-519CEF25-C881-4A65-B6DC-5D8FA55AB13BQ38842938-108B63EB-00C4-47D7-AFD7-B13F929EC046Q39210200-729B8F03-9039-409A-99AA-7F82CF2EC296Q39374988-07D41E78-3D29-447F-B2D2-ECDACA54FBC0
P2860
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@en
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@nl
type
label
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@en
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@nl
prefLabel
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@en
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@nl
P2093
P2860
P356
P1476
The human equilibrative nucleo ...... dhood acute myeloid leukaemia.
@en
P2093
B E S Gibson
E R van Wering
G J L Kaspers
G J Peters
J P P Meijerink
R Broekhuizen
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602881
P407
P577
2005-12-01T00:00:00Z